Related to Ipsen and Dicerna to Develop Gene-Silencing Therapeutics for Cancer and Endocrinology

• Phase III Failure for Pfizer NHL Drug
  
• Mayo Clinic, Cancer Genetics Form Diagnostics JV
  
• Empire Genomics Nabs Prostate Cancer Biomarker from Cornell
  
• Mosquitoes Use RNAi to Combat Dengue Virus Infection
  
• Spirogen Receives About $24M for Clinical-Stage Anticancer Drug and Reacquires Development Rights
  
• Menarini to Market Takeda/Ipsen Gout Therapy in 41 European Countries
  
• Ipsen to Pay Inspiration $344M in Funding and Equity Investment as Part of Hemophilia Alliance
  
• Ipsen Licenses Preclinical MSH and Ghrelin Agonist Programs to Rhythm Pharmaceuticals
  
• GTx and Ipsen Expand Toremifene Partnership to Encompass FDA’s Requested 2nd Phase III Trial
  
• BMS to Use Tekmira’s SNALP Technology for Target Validation
  
• GTx and Ipsen Fail to Show Benefit of Toremifene 20 mg in Prostate Cancer
  
• RXi Wins $600K NIAID SBIR Grant for RNAi Therapeutics
  
• Ipsen Acquires Santhera’s Parkinson Drug for €13M Up Front
  
• Arrowhead Ups Ownership in RNAi Subsidiary Calando
  
• Syntaxin Raises £18M to Progress Clostridium Neurotoxin-Based Secretion Inhibitor Pipeline
  
• Dicerna and Kyowa Hakko Kirin Expand Collaboration into Immunologic and Inflammatory Diseases
  
• GTx and Ipsen End Prostate Cancer Collaboration due to Costs of FDA-Requested Phase III Study
  
• Active Biotech Receives €25M Up Front from Ipsen as Part of Cancer Deal
  
• BMS Expands Deal to Evaluate Tekmira’s RNAi Delivery Technology
  
• Researchers Claim Blocking Cdk1 Makes Wild-Type BRCA1 Cancers Susceptible to PARP Inhibition